A5069682721- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Schizophrenia research and treatment
- Intensive Care Unit Cognitive Disorders
- Attention Deficit Hyperactivity Disorder
- Treatment of Major Depression
- Neurological disorders and treatments
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Sleep and related disorders
- Mental Health Treatment and Access
- Healthcare Decision-Making and Restraints
- Traumatic Brain Injury and Neurovascular Disturbances
- Sleep and Wakefulness Research
- Traumatic Brain Injury Research
- Cholinesterase and Neurodegenerative Diseases
- Anesthesia and Neurotoxicity Research
- Tryptophan and brain disorders
- Health, Environment, Cognitive Aging
- Psychiatric care and mental health services
- Cannabis and Cannabinoid Research
- Advanced Neuroimaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Blood Pressure and Hypertension Studies
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2016-2025
Johns Hopkins Bayview Medical Center
2013-2024
Southern Connecticut State University
2022
RELX Group (Netherlands)
2021
Institute of Navigation
1950-2020
Kennedy Krieger Institute
2020
Institute of Behavioral Sciences
2018
Queen's University Belfast
2018
University of Zurich
2018
We studied the effects of low-frequency transcranial magnetic stimulation (TMS) on motor cortex excitability in humans. TMS at 0.1 Hz for 1 hour did not change cortical excitability. Stimulation 0.9 15 minutes (810 pulses), similar to parameters used induce long-term depression (LTD) slice preparations and vivo animal studies, led a mean decrease evoked potential (MEP) amplitude 19.5%. The lasted least after end stimulation. mechanism underlying this may be LTD. TMS-induced reduction has...
A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability effects on biomarker (plasma Aβ40 Aβ42, CSF Aβ40, tau, phospho-tau 181) volumetric MRI outcomes (primary outcomes) clinical (secondary outcomes).
Agitation is common, persistent, and associated with adverse consequences for patients Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.The primary objective was to evaluate the efficacy of citalopram agitation in Key secondary objectives examined effects on function, caregiver distress, safety, cognitive tolerability.The Citalopram Disease Study (CitAD) a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186...
Background: Mild behavioral impairment (MBI) is a construct that describes the emergence at ≥50 years of age sustained and impactful neuropsychiatric symptoms (NPS), as precursor to cognitive decline dementia. MBI NPS any severity, which are not captured by traditional psychia tric nosology, persist for least 6 months, occur in advance or concert with mild impairment. While detection description has been operationalized International Society Advance Alzheimer's Research Treatment –...
<h3>Objective</h3> The association of primary oncologist specialty, medical oncology versus gynecologic oncology, on intensity care at the end life in elderly patients with cancer is unclear. <h3>Methods</h3> This retrospective cohort study used Surveillance, Epidemiology and End Results-Medicare (SEER-M) data. Subjects were fee-for-service Medicare enrollees aged 65 years older who died a between January 2006 December 2015. outcome was composite score for high-intensity received last month...
Background: Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional circuits.The safety and efficacy DBS in dementia unknown.Objective: To assess memory circuits as a treatment for patients with mild Alzheimer's disease (AD).Methods: We evaluated active "on" versus sham "off" bilateral directed at fornix-a major fiber bundle brain's circuit-in randomized, double-blind trial (ClinicalTrials.govNCT01608061) 42 AD.We measured cognitive function cerebral glucose metabolism...
Abstract Introduction Neuropsychiatric symptoms (NPSs) are nearly universal in cognitive disorders. The mild behavioral impairment construct postulates that NPS may be the first symptom of impending dementia. Methods Participants were cognitively normal volunteers followed up approximately annually at Alzheimer's Disease Centers, who assessed on Inventory and had least one follow‐up visit during which they diagnosed with (MCI) or Descriptive statistics used to determine sequencing presence...
Apathy is common in neurocognitive disorders (NCD) but NCD-specific diagnostic criteria are needed.The International Society for CNS Clinical Trials Methodology Work Group convened an expert group and sought input from academia, health-care, industry, regulatory bodies. A modified Delphi methodology was followed, included extensive literature review, two surveys, meetings at international conferences, culminating a consensus meeting 2019.The final reached with more than 80% agreement on all...
In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease. We further assessed this finding the Apathy Dementia Methylphenidate Trial (ADMET).Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling disease participants (NINCDS-ADRDA criteria) with assigned to 20 mg daily or placebo, conducted from June 2010 December 2011. Primary outcomes were change Evaluation Scale (AES) score and modified Disease Cooperative Study-Clinical...
Objectives Based on a multifactorial model of delirium, to compare the types and magnitude pre‐ intraoperative predisposing factors for incident delirium in stratified sample individuals with without preoperative dementia undergoing acute hip fracture repair. Design Prospective cohort study. Setting Academic medical center. Participants Four hundred twenty‐five (mean age 80.2 ± 6.8, 73.2% female, 33.1% probable dementia) admitted multidisciplinary repair service. Measurements A research...
Objective: To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in treatment dementia-related neuropsychiatric symptoms (NPS). Methods: This is a randomized, double-blind, placebo-controlled study. Patients with dementia clinically relevant NPS were randomly assigned to receive THC 1.5 mg or matched placebo (1:1) 3 times daily for weeks. Primary outcome was change Neuropsychiatric Inventory (NPI), assessed at baseline after 14 21 days. Analyses based on...
Aggression after traumatic brain injury (TBI) is common but not well defined.Sixty-seven participants with first-time TBI were evaluated for aggression within 3 months of injury.The prevalence was found to be 28.4%, predominantly verbal aggression.Post-TBI associated new-onset major depression (pϭ0.02),poorer social functioning (pϭ0.04), and increased dependency in activities daily living (pϭ0.03),but a history substance abuse or adult/childhood behavioral problems.Implications the study...
<h3>Importance</h3> Postoperative delirium is the most common complication following major surgery in older patients. Intraoperative sedation levels are a possible modifiable risk factor for postoperative delirium. <h3>Objective</h3> To determine whether limiting during spinal anesthesia reduces incident overall. <h3>Design, Setting, and Participants</h3> This double-blind randomized clinical trial (A Strategy to Reduce Incidence of Delirum Elderly Patients [STRIDE]) was conducted from...
Objective The use of psychotropic medications in Alzheimer's disease (AD) has been associated with both deleterious and potentially beneficial outcomes. We examined the longitudinal association medication cognitive, functional, neuropsychiatric symptom (NPS) trajectories among community‐ascertained incident AD cases from Cache County Dementia Progression Study. Methods A total 230 participants were followed for a mean 3.7 years. Persistency index (PI) was calculated all antidepressants,...